CRVS

Corvus Pharmaceuticals, Inc.
CAPPED RATING

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.

Corvus Pharmaceuticals, Inc. (CRVS) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D). The rating has held at C- for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.0 / 5.0
C-
Value
C+
Factor Score 2.5 / 5.0
Growth
D
Factor Score 1.2 / 5.0
Profitability
D+
Factor Score 1.8 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -10.3
EV / EBITDA -11.2
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -24.4%
Price Return 12M 49.6%
Catalyst Signal 0.00
Market Cap $959.1M
TTM Revenue N/A
Price / Sales N/A
ROE -45.9%

Historical Factor Score Progression

Held C- for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C+ (2.5) D (1.2) D+ (1.8) C- (2.0) C+ (2.6) C- (2.0)
2026-11-04 C+ (2.5) D (1.2) C- (1.9) C- (2.0) C+ (2.7) C- (2.1)
2026-10-28 C+ (2.5) D (1.2) C- (1.9) C (2.3) C+ (2.7) C- (2.1)
2026-10-21 C+ (2.5) D (1.2) C- (1.9) C (2.2) C+ (2.6) C- (2.1)
2026-10-14 C+ (2.5) D (1.2) C- (1.9) C (2.3) C+ (2.6) C- (2.1)
Page 1 of 4